Here is the design of a clinical trial:

Official Title: Randomized, Controlled, Multicenter Studies of the Effects of Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis

Included conditions:
- Pancreatitis, Acute
- Hypertriglyceridemia

Study Armgroups:
- {'label': 'Group Insulin', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Insulin']}
- {'label': 'Group Aphesis', 'type': 'EXPERIMENTAL', 'interventionNames': ['Device: Aphesis']}

Interventions:
- {'type': 'DRUG', 'name': 'Insulin', 'description': 'Insulin infusion for subjects in Group Insulin.', 'armGroupLabels': ['Group Insulin']}
- {'type': 'DEVICE', 'name': 'Aphesis', 'description': 'Aphesis for subjects in Group Aphesis.', 'armGroupLabels': ['Group Aphesis']}

Primary Outcomes:
- {'measure': 'serum TG', 'description': 'Elimination of serum triglyceride.', 'timeFrame': 'every 4 hours in first 3 days'}

Please estimate the sample size based on the assumption: 
two-sided significance level of 5%, statistical power of 80%, 20% increase to account for drop-out and missing data
Sample size calculation
        The Bi-TPAI trial is a non-inferiority randomized controlled trial. Respective studies and series reported 60â72% of cases with TGâ<â5.6âmmol/l after one or two sessions of plasmapheresis [4, 12]. A total of 176 participants (88 per group) is required to show non-inferiority of intensive insulin therapy compared to plasmapheresis therapy, with a two-sided significance level of 5% and statistical power of 80%. To account for drop-out and missing data, the sample size is increased by 20% to a final sample size of 220 participates (110 per group).